PERSPECTIVE THERAPEUTICS, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- PERSPECTIVE THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2021-03-31 was $47.90M.
- PERSPECTIVE THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2020-12-31 was $8.47M.
- PERSPECTIVE THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2018-09-30 was $7.49M.
- PERSPECTIVE THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2023 was $364.00K.
- PERSPECTIVE THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2021 was $56.38M, a 6350.23% increase from fiscal 2020.
- PERSPECTIVE THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2020 was $874.00K, a 88.14% decline from fiscal 2019.
- PERSPECTIVE THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2019 was $7.37M, a 1438.62% increase from fiscal 2018.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2023-12-31 | $364.00K 10-K · filed 2024-03-28 | |
| 2021-06-30 | $56.38M 10-KT · filed 2023-05-01 | |
| 2021-03-31 | $47.90M 10-Q · filed 2022-05-13 | |
| 2020-12-31 | $8.47M 10-Q · filed 2022-05-13 | |
| 2020-06-30 | $874.00K 10-KT · filed 2023-05-01 | |
| 2019-06-30 | $7.37M 10-K · filed 2021-09-27 | |
| 2018-09-30 | $7.49M 10-Q · filed 2020-05-13 | |
| 2018-06-30 | $479.00K 10-K · filed 2020-09-25 | |
| 2014-06-30 | $1.80M 10-K · filed 2016-09-09 | |
| 2011-06-30 | $250.63K 10-K/A · filed 2012-10-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |